# Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML

> **NCT07735117** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 168 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndromes (MDS)

## Interventions

- **DRUG:** Mitoxantrone Hydrochloride Liposome
- **DRUG:** Cytarabine
- **DRUG:** Granulocyte Colony-Stimulating Factor(G-CSF)
- **DRUG:** Venetoclax
- **DRUG:** Venetoclax
- **DRUG:** azacitidine

## Key facts

- **NCT ID:** NCT07735117
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2028-07-20
- **Final completion:** 2029-07-31
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2026-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07735117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07735117, "Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07735117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*